Díez-Fernández A, et al. - Researchers evaluated the efficacy of insulin glargine 300 ui/mL (Gla-300) in reducing nocturnal hypoglycemia and improving glycemic control in type 1 and type 2 diabetics vs insulin glargine 100 ui/mL (Gla-100). Until July 4, 2018, they systematically searched Medline, Embase, and Web of Science databases, as well as the Cochrane Central Register of Controlled Trials, for relevant studies. They identified nine eligible studies, which included 3,977 adult patients. In these adult patients with type 1 and type 2 diabetes, they found that Gla-300 decreased the incidence of nocturnal hypoglycemia with slight improvements in glycemic control vs Gla-100. Overall, there was a small decrease in HbA_1c levels in favor of Gla-300 in the pooled sample.